Literature DB >> 31191864

How mithramycin stereochemistry dictates its structure and DNA binding function.

Caixia Hou1, Jürgen Rohr1, Sean Parkin2, Oleg V Tsodikov1.   

Abstract

An aureolic acid natural product mithramycin (MTM) has been known for its potent antineoplastic properties. MTM inhibits cell growth by binding in the minor groove of double-stranded DNA as a dimer, in which the two molecules of MTM are coordinated to each other through a divalent metal ion. A crystal structure of an MTM analogue, MTM SA-Phe, in the active metal ion-coordinated dimeric form demonstrates how the stereochemical features of MTM define the helicity of the dimeric scaffold for its binding to a right-handed DNA double helix. We also show crystallographically and biochemically that MTM, but not MTM SA-Phe, can be inactivated by boric acid through formation of a large macrocyclic species, in which two molecules of MTM are crosslinked to each other through 3-side chain-boron-sugar intermolecular bonds. We discuss these structural and biochemical properties in the context of MTM biosynthesis and the design of MTM analogues as anticancer therapeutics.

Entities:  

Year:  2019        PMID: 31191864      PMCID: PMC6533888          DOI: 10.1039/c9md00100j

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  36 in total

1.  Characterization of kinetics and products of the Baeyer-Villiger oxygenase MtmOIV, the key enzyme of the biosynthetic pathway toward the natural product anticancer drug mithramycin from Streptomyces argillaceus.

Authors:  Miranda Gibson; Mohammad Nur-e-alam; Fredilyn Lipata; Marcos A Oliveira; Jürgen Rohr
Journal:  J Am Chem Soc       Date:  2005-12-21       Impact factor: 15.419

2.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

Review 3.  The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives.

Authors:  Felipe Lombó; Nuria Menéndez; José A Salas; Carmen Méndez
Journal:  Appl Microbiol Biotechnol       Date:  2006-09-30       Impact factor: 4.813

4.  Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.

Authors:  Patrick J Grohar; Girma M Woldemichael; Laurie B Griffin; Arnulfo Mendoza; Qing-Rong Chen; Choh Yeung; Duane G Currier; Sean Davis; Chand Khanna; Javed Khan; James B McMahon; Lee J Helman
Journal:  J Natl Cancer Inst       Date:  2011-06-08       Impact factor: 13.506

5.  Evaluation of complexation of metal-mediated DNA-binding drugs to oligonucleotides via electrospray ionization mass spectrometry.

Authors:  M L Reyzer; J S Brodbelt; S M Kerwin; D Kumar
Journal:  Nucleic Acids Res       Date:  2001-11-01       Impact factor: 16.971

6.  Association of antitumor antibiotics, mithramycin and chromomycin, with Zn(II).

Authors:  Pukhrambam Grihanjali Devi; Sudipta Pal; Raja Banerjee; Dipak Dasgupta
Journal:  J Inorg Biochem       Date:  2006-09-20       Impact factor: 4.155

7.  Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis.

Authors:  Lily L Remsing; Ana M González; Mohammad Nur-e-Alam; M José Fernández-Lozano; Alfredo F Braña; Uwe Rix; Marcos A Oliveira; Carmen Méndez; José A Salas; Jürgen Rohr
Journal:  J Am Chem Soc       Date:  2003-05-14       Impact factor: 15.419

8.  Crystal structure of the [Mg2+-(chromomycin A3)2]-d(TTGGCCAA)2 complex reveals GGCC binding specificity of the drug dimer chelated by a metal ion.

Authors:  Ming-Hon Hou; Howard Robinson; Yi-Gui Gao; Andrew H-J Wang
Journal:  Nucleic Acids Res       Date:  2004-04-23       Impact factor: 16.971

9.  Crystal structure of Baeyer-Villiger monooxygenase MtmOIV, the key enzyme of the mithramycin biosynthetic pathway .

Authors:  Miranda P Beam; Mary A Bosserman; Nicholas Noinaj; Marie Wehenkel; Jürgen Rohr
Journal:  Biochemistry       Date:  2009-06-02       Impact factor: 3.162

10.  Durhamycin A, a potent inhibitor of HIV Tat transactivation.

Authors:  Hiranthi Jayasuriya; Russell B Lingham; Pia Graham; Donette Quamina; Lucia Herranz; Olga Genilloud; Magda Gagliardi; Renee Danzeisen; Joanne E Tomassini; Deborah L Zink; Ziqiang Guan; Sheo B Singh
Journal:  J Nat Prod       Date:  2002-08       Impact factor: 4.050

View more
  2 in total

1.  Discovery of a Cryptic Intermediate in Late Steps of Mithramycin Biosynthesis.

Authors:  Ryan Wheeler; Xia Yu; Caixia Hou; Prithiba Mitra; Jhong-Min Chen; Frank Herkules; Dmitri N Ivanov; Oleg V Tsodikov; Jürgen Rohr
Journal:  Angew Chem Int Ed Engl       Date:  2019-11-27       Impact factor: 15.336

2.  Mithramycin delivery systems to develop effective therapies in sarcomas.

Authors:  Óscar Estupiñán; Enrique Niza; Iván Bravo; Verónica Rey; Juan Tornín; Borja Gallego; Pilar Clemente-Casares; Francisco Moris; Alberto Ocaña; Verónica Blanco-Lorenzo; Mar Rodríguez-Santamaría; Aitana Vallina-Álvarez; M Victoria González; Aida Rodríguez; Daniel Hermida-Merino; Carlos Alonso-Moreno; René Rodríguez
Journal:  J Nanobiotechnology       Date:  2021-09-06       Impact factor: 10.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.